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摘  要 
艾滋病(Acquired Immune Deficiency Syndrome, AIDS)是由人类免疫缺陷病
毒(Human Immunodeficiency Virus, HIV)感染导致人体免疫机能缺陷而易于发生


















羰基丁酯(D-galactosyl-4-[(4-{[(cholestan-3-yloxy)carbonyl] amino}butyl) amino]-4- 




















出仪整粒技术制备 AZTS 脂质体。最优处方为磷脂含量为 5%(W/V)，药脂比为
1:20(W/W)，总胆固醇与磷脂的质量比为 1:4，GCOE 与胆固醇的质量比为 2:1。
制备的脂质体包封率高(85%以上)，粒径较小且均一(平均粒径 180nm，多分散指
数 0.371)。 
    3. 对 GCOE 修饰的脂质体进行了初步的体外靶向性评价。GCOE 对小鼠巨




(Doxorubicine, DOX)作为荧光探针制备荧光脂质体，对 GCOE 修饰的荧光脂质
体与巨噬细胞的体外亲和力作了定性评价；同时，用 MTT 法对 GCOE 修饰的
AZTS 脂质体、DOX 脂质体与巨噬细胞的体外亲和力作了定量评价。结果表明，
经 GCOE 修饰后，脂质体与巨噬细胞的亲和力显著增强，能携载更多的药物进
入巨噬细胞内。GCOE 能实现主动靶向巨噬细胞的能力，预期经 GCOE 修饰的
脂质体在抗 HIV 治疗中有良好的应用前景。 
















Human immunodeficiency virus (HIV) is a lentivirus that causes acquired 
immunodeficiency syndrome (AIDS), which progressive failure of the immune 
system allows life-threatening opportunistic infections and malignancies. Although 
highly active antiretroviral therapy (HAART) is able to inhibit the replication of the 
HIV , reduce the morbidity and mortality of AIDS, drugs disable eradicating HIV, 
insufficient concentrations in virus reservoirs, multi-drug resistance against anti-HIV 
drugs in long-term therapy are nonnegligible problems. Therefore, the challenges 
associated with optimizing drug delivery system for the effective treatment of AIDS is 
in the limelight. Since macrophage plays a key role in HIV virus reservoirs, strategy 
aimed at drug delivery systems for targeting macrophage is highly attractive.  
Liposomes are the most promising vector in anti-HIV therapy both in laboratory 
and clinic. It can improve drug’s delivery in vivo, that enhance the therapeutic effect 
of anti-HIV drugs. While plain liposomes is passive targeting for mononuclear 
phagocyte system(MPS), in order to specifically target HIV-infected cells, this work 
designs a new type of liposome, D-galactosyl-4-[(4-{[(cholestan-3-yloxy)carbonyl] 
amino}butyl)amino]-4-oxobutanoate(GCOE) modified azidothymidine stearate 
(AZTS) loaded liposomes, which can specific binding with galactose particle receptor 
on macrophage membranes, exhibiting active targeting ability to macrophages. We 
evaluate the drug delievery system’s active targeting ability in vitro, the results are 
same with expectations. This new type of liposome is expected to highly selective 
against HIV reservoirs (macrophage), reduce the probability of drug-resistant strains 
in AIDS treatment process. The new type of liposome can be used as the ideal 
formulation of anti-AIDS drugs as well as targeted drug delivery formulations of 
other antiviral drugs, has a good application prospects. 
The following parts are included in this paper. 















prodrug of Azidothymidine(AZT) and D-galactosyl-4-[(4-{[(cholestan-3-yloxy) 
carbonyl]amino}butyl)amino]-4-oxobutanoate(GCOE) as a ligand that active 
targeting macrophage via galactose particle receptor. Compared with AZT, lipid 
solubility of AZTS is significantly improved (logPoct = 5.22), which more suitable for 
the preparation of the liposome, enhance the efficiency of AZTS-loaded liposomes 
with little drug leakage. The reaction conditions during the procedure of GCOE 
synthesis are mild and easy to operate, GCOE can be effectively isolated and purified 
using normal phase silica gel column.    
 2. Establish a HPLC method in vitro for AZTS determination, and AZTS 
liposome entrapment efficiency of the method (filter membrane separation-HPLC 
detection of drug content), using the thin film dispersion or ethanol inpouring method, 
combined with extrusion of crude liposomes. The best prescription is: phospholipids 
account for 5% of the prescription(W/V), with the ratio of drug and total lipid is 
1:20(W/W),the ratio of total cholesterol and phospholipid is 1:4(W/W), the ratio of 
GCOE and cholesterol is 2:1(W/W). The entrapment efficiency of GCOE modified 
AZTS-loaded liposomes is above 85%, while with small and uniform particle 
size(mean particle size is 180 nm, polydipersity index is 0.371). 
3. GCOE modified liposomes were prepared for preliminarily evaluate the 
targeting ability of GCOE in vitro. GCOE exhibited good biocompatibility and no 
cytotoxicity to murine macrophage cell line RAW 264.7. GCOE acts as a anchor on 
liposome’s surface, which is reflected by its galactosyl like group’s specific 
agglutination with Ricinus communis agglutinin. Meanwhile, thanks to doxorubicine 
(DOX) has a large conjugated system which exciting stable fluorescence, it was used 
as a fluorescent probe to prepared fluorescent liposomes in this study due to AZTS 
shows no fluorescence. In contrast with plain liposome and free drug, GCOE 
modified liposomes exhibit higher affinity with macrophage both in qualitative and 
quantitative uptake of GCOE modified liposomes studies on RAW264.7 cells in vitro. 
The GCOE modified liposomes were able to carry more drugs into HIV 
reservoirs(macrophage) and showed higher affinity with macrophage. The results 















macrophage targeting drug carrier in anti-HIV therapy. 
Keywords:azidothymidine stearate; galactose modified lipid; active targeting 
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艾滋病，即获得性免疫缺陷综合症(Acquired Immune Deficiency Syndrome, 
AIDS)，是由人免疫缺陷病毒(Human Immunodeficiency Virus, HIV)感染导致人体
免疫机能缺陷而易于发生机会性感染和肿瘤的临床综合征。 
自 1981 年美国发现首例 AIDS 患者以来，AIDS 已逐渐成为人类前所未有的
最具毁灭性疾病，被称为“当代瘟疫”和“超级癌症”，该病已引起世界卫生组织




疫情的报告(图 1.1)，截止 2010 年底，大约有 3400 万人携带艾滋病毒。同年，




前无治疗 AIDS 的特效药和预防 AIDS 的有效疫苗，死于艾滋病并发症的人数仍
居高不下。 
 
图 1.1  HIV 病毒流行的关键指标(2002-2010 年) 















因此，寻求有效治疗 AIDS 的方法和药物仍是医药工作者面临的紧迫任务。 
1.1.2 AIDS 发病机制 
HIV 属逆转录病毒科中慢病毒属中的灵长类免疫缺损病毒亚属[2]，在体外不
能繁殖，需借助人体细胞复制再生。HIV 主要侵犯宿主的 CD4+T 细胞以及表达
CD4 分子的单核-巨噬细胞、树突状细胞和神经胶质细胞等[3]。HIV 通过病毒糖
蛋白 gpl20/gp41 与在被感染细胞的细胞膜表面同时表达的 CD4 分子和辅助受体
(CXCR4 和 CCR5)进行识别，形成 CD4-gp120-CXCR4/CCR5 三分子复合物，导
致 gp120 构象改变，暴露出被其掩盖的 gp41，与宿主细胞膜融合，形成 HIV-融
合肽，使病毒核心进入靶细胞，进行逆转录、整合、转录、翻译、组装蛋白、溢
出(或储存和隐藏)等步骤(图 1.2)，侵入细胞并损伤宿主的免疫系统，而宿主的免





不明确的病变，如 HIV 相关的肺、心脏、肠、肾病等[5]。 
 
图 1.2  HIV-1 在巨噬细胞和 T 细胞中的复制周期 






















病毒法(Highly Active Antiretroviral Therapy, HAART)，俗称“鸡尾酒”疗法。
HAART 疗法通常是根据药物的毒性、耐药性、实用性、可行性以及病人的具体
情况来制定各自的给药方案，在已有的抗逆转录病毒药物(Antiretrovirus Drugs，
ARV)基础上，组成以 2种核苷类逆转录酶抑制剂(Nucleoside Reverse Transcriptase 
Inhibitors, NRTIs)为骨架，联合非核苷类逆转录酶抑制剂(Non-Nucleoside Reverse 
Transcriptase Inhibitors, NNRTIs)或蛋白酶抑制剂(Protease Inhibitors, PIs)的方案，






































表 1.1 已上市的抗逆转录病毒药物(ARV) 
Table 1.1 The antiretroviral drugs approved into market 















融合抑制剂(FIs) 恩夫韦肽 注射剂 










因此，寻找高效低毒的抗 HIV 新药，以及针对 HIV 贮库开发新的给药系统
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